Management of patients with electrical storm at Kyorin University Authors: Chutimon Junkrasien, Kyoko Soejima, Akiko Ueda, Yumi Katsume Published: 2026 ABSTRACT Electrical storm (ES) refers to a life-threatening state of cardiac electrical instability, and occurrence of three or more episodes of ventricular tachycardia (VT) or ventricular fibrillation (VF) within 24-h period. Contemporary management extends beyond antiarrhythmic therapy and catheter ablation to include autonomic modulation, rehabilitation, and longitudinal patient engagement. We present two illustrative cases: one with non-ischemic cardiomyopathy with refractory VT storm, and the other with post–myocardial infarction VF storm, to demonstrate a practical stepwise management framework from acute stabilization to long-term surveillance. These cases highlight the importance of early sedation, optimized pharmacologic therapy, neuromodulation, tailored ablation strategies, rehabilitation, and structured continuity of care. Introduction ES is a critical medical emergency defined by the occurrence of three or more episodes of sustained VT or VF within 24-h period. This state of severe electrical instability carries a high risk of both sudden and non-sudden cardiac death and often is a sign of transition to advanced heart failure. Contemporary international guidelines emphasize immediate hemodynamic stabilization, sympathetic suppression, antiarrhythmic therapy, and early consideration of catheter ablation [1,2]. However, optimal care extends beyond arrhythmia control. A structured, flow-based management model from sedation to home monitoring after the patient discharge, may improve both survival and quality of life. We illustrate this concept through two complementary cases. Pathophysiology of ES ES represents the convergence of a vulnerable myocardial substrate, transient triggering events, and dynamic autonomic imbalance. The pathophysiologic substrate varies according to underlying heart disease but typically involves areas of scar-related slow conduction for reentrant circuits or regions of Purkinje network hyperexcitability initiating triggered activity [3]. In structural heart disease, heterogeneous fibrosis creates zones of anisotropic conduction and functional block, facilitating macro-reentrant VT. Progressive remodeling, inflammation, and neurohormonal activation further destabilize conduction properties and reduce VF threshold [4]. In ischemic settings, acute border-zone injury enhances dispersion of repolarization and may promote both reentry and triggered activity through delayed afterdepolarizations. A central and unifying mechanism in ES is increased sympathetic activity. Recurrent implantable cardioverter defibrillator (ICD) shocks, pain, anxiety, and hemodynamic compromise amplify catecholamine release, increasing intracellular calcium loading, shortening action potential duration heterogeneously, and promoting triggered activity and reentry [5]. Experimental and clinical studies have demonstrated that sympathetic blockade, such as beta-blockade and cardiac sympathetic denervation, reduces arrhythmia burden and improves outcomes in refractory storm [6,7]. Importantly, ES is not static; it represents a dynamic state in which substrate, triggers, and autonomic tone interact. Thus, successful management requires simultaneous interruption of sympathetic amplification, suppression of triggers, and definitive modification of the arrhythmogenic substrate. Cases Case 1: non-ischemic cardiomyopathy with refractory VT storm A 72-year-old man with non-ischemic cardiomyopathy (NICM) underwent implantation of a cardiac resynchronization therapy defibrillator (CRT-D) for secondary prevention four years prior to presentation. One year before the current admission, he developed sustained monomorphic VT requiring appropriate CRT-D shocks and underwent endocardial radiofrequency ablation (RFA) at an outside institution. As per the report, VT was mapped and the activation showed the earliest activation at the endocardial left ventricular (LV) apex. RF application at the earliest site terminated VT, but no detailed substrate mapping was conducted. Three months prior to the admission, VT with identical morphology (Fig. 1, panel B) recurred, resulting in multiple CRT-D shocks. Antiarrhythmic therapy was switched from amiodarone to sotalol. Despite partial suppression with dexmedetomidine and bilateral stellate ganglion block (SGB) using mepivacaine, shock frequency increased, and he was transferred to our center for further management.Fig. 1Electrocardiogram of baseline rhythm and during VTPanel A; baseline rhythm with atrial pacing and biventricular pacing.Panel B; sustained monomorphic VT with markedly wide QRS complexes, slurred onset and intrinsicoid deflection. There is negative concordance from V2-V6 indicating LV apical in origin. Broad QRS duration supports an epicardial exit. Electrocardiogram of baseline rhythm and during VT Panel A; baseline rhythm with atrial pacing and biventricular pacing. Panel B; sustained monomorphic VT with markedly wide QRS complexes, slurred onset and intrinsicoid deflection. There is negative concordance from V2-V6 indicating LV apical in origin. Broad QRS duration supports an epicardial exit. On admission, therapy included oral amiodarone, carvedilol, intravenous lidocaine, and twice daily stellate ganglion phototherapy [8]. Recurrent VT required repeated cardioversion under sedation with propofol and dexmedetomidine. Given refractory ES, catheter ablation with planned epicardial access was scheduled. Electrophysiologic findings Following exclusion of significant coronary disease, epicardial access was obtained. Substrate mapping was performed using HD grid catheter during LV only pacing to identify regions of isochronal late activation located along LV lateral wall, apex, and inferior wall. Fragmented electrograms as well as double and triple potentials were identified in these areas. The most delayed activation was observed near the LV apex (Fig. 2). With activation and entrainment mapping, reentrant mechanism of the VT was confirmed. RFA was delivered at the central isthmus site, resulting in VT termination (Fig. 2). However, after further power escalation, an audible stream pop occurred. A small pericardial effusion was detected, leading to termination of the procedure. The patient stayed stable without additional pericardial effusion accumulation.Fig. 2Isochronal late activation map (ILAM) during LV pacingILAM demonstrates a broad region of deceleration, characterized by crowding of isochrones within the LV substrate.The blue tag indicates the site where entrainment identified a critical isthmus, with RFA resulting in VT termination. The red tags represent RFA sites, predominantly clustered within the region of isochronal crowding, consistent with a critical slow conduction zone. The yellow tag denotes the site of VT termination without global capture during the second ablation session. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) Isochronal late activation map (ILAM) during LV pacing ILAM demonstrates a broad region of deceleration, characterized by crowding of isochrones within the LV substrate. The blue tag indicates the site where entrainment identified a critical isthmus, with RFA resulting in VT termination. The red tags represent RFA sites, predominantly clustered within the region of isochronal crowding, consistent with a critical slow conduction zone. The yellow tag denotes the site of VT termination without global capture during the second ablation session. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) VT recurred the following day despite medical therapy. A redo ablation was performed under general anesthesia with epicardial access. During entrainment, termination without global propagation was repeatedly observed (Fig. 2), suggesting that the critical isthmus was likely located in this region [9], and additional RFA in adjacent area resulted in non-inducibility of VT and elimination of the delayed potential. Guideline-directed heart failure therapy was continued, CRT-D generator replacement was completed, and structured rehabilitation was initiated prior to discharge. The patient was discharged home after 17 days of rehabilitation. Case 2: VF storm after recent myocardial infarction A 60-year-old man with diabetes mellitus and chronic kidney disease was admitted for pneumonia in the setting of a recent myocardial infarction and reduced LV ejection fraction. Coronary angiography revealed significant left anterior descending artery stenosis. Percutaneous coronary intervention (PCI) was initially deferred due to worsening renal function. However, he subsequently developed two VF episodes, prompting emergency PCI with complete revascularization. Despite revascularization and initiation of oral amiodarone, he developed VF storm, requiring intubation, deep sedation (fentanyl and propofol), and repeated defibrillation. Bradycardia and QT prolongation necessitated discontinuation of amiodarone. Continuous monitoring revealed frequent multifocal premature ventricular contractions (PVCs) with right bundle branch block morphology and varying axes, suggesting a Purkinje origin. Temporary ventricular pacing was attempted but caused hypotension requiring vasopressor support. The patient has received more than 10 defibrillation and urgent catheter ablation was decided. Electrophysiologic findings Substrate mapping demonstrated a broad LV low-voltage region in the anteroseptal and inferoseptal wall. Three PVCs morphologies with right bundle branch block patterns were identified; PVC1 (inferior axis), PVC2 (superior axis) and PVC3 (intermediate axis) (Fig. 3). PVC1 and PVC3 were reproducible, whereas PVC2 occurred infrequently; therefore PVC1 and PVC3 were selected as the primary ablation targets. RFA was first performed for PVC3, located near the anterior wall of LV mid septum, followed by ablation of PVC1 near the inferior wall of the LV mid septum (Fig. 4). PVCs burden markedly decreased thereafter. After ablation, no ventricular arrhythmias were inducible with programmed stimulation and isoproterenol infusion. No further VF episodes occurred. Sedation and temporary pacing were gradually discontinued. After staged rehabilitation and shared decision-making regarding secondary prevention ICD therapy, which the patient refused, he was discharged with structured follow-up and direct contact instructions.Fig. 3PVC-triggered VF.Left panel: PVC1 exhibiting an inferior axis morphology.Middle panel: PVC2 demonstrates a superior axis morphology, occurring less frequently. Right panel: PVC3 showing an intermediate axis morphology.Fig. 4Intracardiac electrograms during PVC3 demonstrating the site of earliest ventricular electrogram (−56 ms), with a preceding pre-potential recorded on the ablation catheter. PVC-triggered VF. Left panel: PVC1 exhibiting an inferior axis morphology. Middle panel: PVC2 demonstrates a superior axis morphology, occurring less frequently. Right panel: PVC3 showing an intermediate axis morphology. Intracardiac electrograms during PVC3 demonstrating the site of earliest ventricular electrogram (−56 ms), with a preceding pre-potential recorded on the ablation catheter. Stepwise management framework Autonomic suppression ES reflects a state of profound autonomic imbalance, in which heightened sympathetic activation lowers the VF threshold, shortens action potential duration, and promotes dispersion of repolarization, thereby facilitating both triggered activity and reentry [2]. Sustained adrenergic stimulation further increases intracellular calcium loading and myocardial oxygen demand, perpetuating a self-reinforcing cycle of ischemia and arrhythmia recurrence. Accordingly, early autonomic suppression is a central therapeutic priority. Deep sedation reduces central sympathetic outflow, attenuates circulating catecholamines, and mitigates arrhythmogenic triggers. In clinical practice, intravenous sedative agents can acutely suppress ventricular arrhythmia burden, particularly in patients experiencing recurrent defibrillator shocks, which themselves exacerbate adrenergic activation [10]. Endotracheal intubation should be considered early in refractory cases to facilitate controlled ventilation, optimize metabolic status, and enable safe delivery of deep sedation. Importantly, alleviation of pain and psychological distress from repeated ICD shocks contributes significantly to sympathetic attenuation. Beyond sedation, targeted neuromodulation provides additional sympatholytic control. SGB has emerged as an effective adjunctive therapy in patients with refractory ES who remain unstable despite antiarrhythmic drugs and deep sedation. By attenuating sympathetic cardiac input, this approach can reduce ventricular arrhythmia burden and defibrillator shocks within hours, thereby stabilizing patients and facilitating optimization of medical therapy or progression to definitive catheter ablation. In addition to conventional SGB, noninvasive approaches such as low-level laser–mediated stellate ganglion phototherapy have been reported to achieve comparable sympatholytic effects, offering a potential alternative when invasive procedures are not feasible or require repetition [8]. Importantly, the effects of SGB are often transient, and repeated or continuous interventions may be required as a bridge to definitive substrate ablation. Consistent with this framework, recent clinical reports further support the role of sympathetic modulation as a temporizing but effective strategy in refractory ES. For example, a case of dilated cardiomyopathy demonstrated successful control of refractory ventricular arrhythmias through combined autonomic modulation, allowing stabilization and subsequent definitive management [11]. Similarly, in our cases, integrated autonomic suppression—through deep sedation and stellate ganglion phototherapy—provided temporary arrhythmia control, enabling hemodynamic stabilization and creating a therapeutic window for definitive interventions. Recent report of daily phototherapy with a portable device suggested this therapy as a potential treatment option for patients with recurrent VT who might face barriers to catheter ablation [12]. Beta-blockade and intravenous antiarrhythmic therapy Non-selective β-adrenergic blockade may provide more comprehensive sympathetic suppression in ES compared with β1-selective agents, particularly in the setting of advanced heart failure where β1 receptors may be downregulated and β2-mediated signaling remains active [4,6]. By antagonizing both β1 and β2 receptors, agents such as propranolol reduce cyclic AMP–mediated calcium influx, attenuate triggered activity, and blunt peripheral sympathetic facilitation of arrhythmogenesis. Small observational studies and clinical experience suggest that propranolol may suppress recurrent ventricular arrhythmias refractory to selective β-blockade, underscoring the mechanistic rationale for broader adrenergic inhibition in ES [6,9]. Intravenous amiodarone remains the cornerstone of acute pharmacologic therapy in ES due to its multichannel blocking properties, including potassium channel inhibition (prolonging repolarization), sodium channel blockade (reducing conduction velocity), and noncompetitive anti-adrenergic effects [2]. These pleiotropic actions allow amiodarone to target both triggered activity and reentrant circuits, making it effective across a wide spectrum of structural substrates. In contrast, lidocaine, a class Ib sodium channel blocker, is particularly useful in ischemic myocardium, where depolarized resting membrane potentials enhance drug binding and facilitate suppression of ventricular ectopy and polymorphic VT [1,2]. This pharmacodynamic profile explains its preferential utility in acute coronary syndromes or post-infarction ES. Despite these pharmacologic strategies, antiarrhythmic drug therapy often achieves temporary stabilization rather than definitive resolution of ES. While ventricular arrhythmia burden may decrease acutely, recurrence rates remain substantial unless the underlying substrate or autonomic driver is addressed. Accordingly, contemporary management emphasizes early integration of autonomic modulation and catheter ablation when feasible, rather than prolonged reliance on escalating drug regimens alone. Catheter ablation Scar-related VT (case 1) Scar-related VT in non-ischemic cardiomyopathy (NICM) is frequently driven by heterogeneous fibrosis forming slow-conduction channels, often distributed epicardially. Early consideration of epicardial mapping is essential when endocardial ablation fails. Combined endocardial–epicardial approaches and substrate-based strategies such as late activation mapping improve outcomes compared with focal exit site ablation alone [13,14,15]. Pre-procedural cardiac magnetic resonance imaging (CMR) can provide important information regarding scar distribution and the presence of potential epicardial substrate. At our center, we generally perform CMR when the patient's clinical condition and renal function permit and MRI-compatible devices are present. However, CMR may not be feasible in patients with ongoing ES, advanced chronic kidney disease, or when urgent catheter ablation is required. In this patient, prior ablation targeted a presumed exit site at the LV apex without comprehensive substrate modification. Although VT terminated acutely, the absence of substrate mapping likely allowed persistence of deeper or adjacent slow-conduction channels, predisposing to recurrence with identical morphology. The recurrent ES suggested a stable reentrant circuit rather than polymorphic or triggered activity. Given refractory VT despite optimized antiarrhythmic therapy and autonomic modulation, early epicardial access was pursued. Substrate mapping identified regions of isochronal late activation and delayed potentials along the LV lateral and apical epicardium, consistent with critical components of a reentrant circuit. In NICM, targeting late potentials, local abnormal ventricular activities (LAVA), and conducting channels within low-voltage areas has been associated with improved VT-free survival [16,17,18]. The first procedure was limited by hemodynamic instability and procedural complications, underscoring the complexity of epicardial VT ablation in advanced cardiomyopathy. During redo ablation under general anesthesia, elimination of delayed potentials by guided by ILAM resulted in non-inducibility, supporting successful modification of the critical substrate. This case highlights the importance of comprehensive substrate-based ablation, particularly with planned epicardial mapping, in NICM patients with recurrent scar-mediated VT. Furthermore, termination without global propagation suggested a critical epicardial VT isthmus and guided successful ablation. Trigger-driven VF (case 2) VF storm occurring early after myocardial infarction is frequently initiated by Purkinje-related PVCs, particularly arising from surviving Purkinje fibers within the border zone of infarcted myocardium. These PVCs often demonstrate short coupling intervals and variable morphology and can reproducibly trigger polymorphic VT or VF. Identification and elimination of culprit PVCs through catheter ablation has been shown effective for suppression of VF storm and prevention, even when antiarrhythmic therapy and deep sedation fail [19,20,21]. In this case, recurrent VF persisted despite complete revascularization and combined intravenous amiodarone and lidocaine. Continuous telemetry demonstrated frequent multifocal PVCs with right bundle branch block morphology and variable axes. Electrophysiologic mapping identified split Purkinje potentials preceding PVC onset by approximately 100 ms within a septal low-voltage region, confirming a trigger-based mechanism rather than diffuse ischemic instability. Targeted RFA at sites of earliest Purkinje activation resulted in immediate suppression of PVCs and complete cessation of VF, with no inducible ventricular arrhythmia thereafter. This clinical course is characteristic of trigger elimination therapy in post-MI VF storm. Timing of catheter ablation Contemporary evidence increasingly supports earlier referral for ablation in patients presenting with ES, particularly those with scar-related monomorphic VT. Recurrent ICD shocks, prolonged exposure to antiarrhythmic drugs, and persistent sympathetic activation may contribute to progressive myocardial dysfunction and worse clinical outcomes. Therefore, prolonged attempts at pharmacologic suppression alone may delay definitive treatment of the underlying arrhythmogenic substrate [22]. Observational studies have demonstrated that successful VT ablation in patients with ES is associated with significant reductions in VT recurrence, recurrent ES, and mortality. Furthermore, several investigations suggest that earlier ablation following the initial presentation of VT or ES may improve long-term outcomes compared with delayed intervention after repeated arrhythmic events [23]. The randomized PARTITA trial provided important evidence supporting early intervention. In patients with ischemic or nonischemic cardiomyopathy and an ICD, catheter ablation performed immediately after the first appropriate ICD shock significantly reduced the composite endpoint of death or worsening heart failure hospitalization compared with conventional therapy. Although not limited exclusively to ES, these findings support a strategy of earlier substrate modification before recurrent arrhythmias become established [24]. Current expert consensus therefore favors early consultation with an experienced ventricular arrhythmia center when ES persists despite initial stabilization measures. Antiarrhythmic drugs, sedation, and autonomic modulation should often be viewed as bridging therapies that create a therapeutic window for definitive catheter ablation rather than as stand-alone long-term solutions. In patients with incessant VT, recurrent ICD shocks, or failure of first-line antiarrhythmic therapy, ablation should be considered promptly rather than deferred until multiple drug regimens have failed. Advanced strategies in refractory ventricular arrhythmias When conventional trigger ablation or substrate modification fails, escalation strategies may be required, particularly in structurally complex cardiomyopathy [14]. These include:-Epicardial ablation, especially when endocardial ablation fails, or imaging suggest the epicardial substrate-Bipolar ablation for deep intramural circuits-Transcoronary ethanol infusion targeting intramural arrhythmogenic substrate-Surgical or hybrid ablation approaches -Epicardial ablation, especially when endocardial ablation fails, or imaging suggest the epicardial substrate Epicardial ablation, especially when endocardial ablation fails, or imaging suggest the epicardial substrate -Bipolar ablation for deep intramural circuits Bipolar ablation for deep intramural circuits -Transcoronary ethanol infusion targeting intramural arrhythmogenic substrate Transcoronary ethanol infusion targeting intramural arrhythmogenic substrate -Surgical or hybrid ablation approaches Surgical or hybrid ablation approaches In patients with extensive myocardial scar or progressive cardiomyopathy, repeat procedures are common and should be anticipated as part of longitudinal arrhythmia management rather than procedural failure. Multidisciplinary planning and staged strategies often improve long-term VT/VF freedom. Mechanical circulatory support during ES ablation Mechanical circulatory support (MCS), including venoarterial extracorporeal membrane oxygenation (VA-ECMO), Impella, and other ventricular assist devices, has been increasingly utilized in patients with ES and hemodynamically unstable VT. These devices may provide temporary hemodynamic stabilization, facilitate prolonged activation mapping, and permit ablation of otherwise intolerable ventricular arrhythmias. Although temporary MCS may be considered in selected high-risk patients, its routine use before VT ablation remains debated. Reported outcomes from multicenter studies have been variable, with some studies demonstrating improved procedural tolerance but limited evidence for consistent improvement in long-term clinical outcomes. In addition, device-related vascular complications remain a concern. Therefore, at our institution, VA-ECMO or Impella is generally reserved for patients who require MCS because of cardiogenic shock or severe hemodynamic instability rather than being used prophylactically for VT ablation itself. Etiology-specific treatment In selected patients, ES may reflect active myocardial inflammation rather than fixed scar alone. Cardiac sarcoidosis, giant cell myocarditis, immune checkpoint inhibitor myocarditis, and other inflammatory cardiomyopathies can present with recurrent VT/VF and ES. In these settings, treatment directed at the underlying inflammatory process is essential in addition to conventional antiarrhythmic therapy and catheter ablation. Corticosteroids remain the cornerstone of therapy for active cardiac sarcoidosis and giant cell myocarditis. Reduction of inflammatory activity may decrease arrhythmia burden and improve ventricular function. Additional immunosuppressive agents such as methotrexate, azathioprine, mycophenolate mofetil, or biologic therapies may be required in steroid-refractory cases. Importantly, catheter ablation alone is often insufficient during periods of active inflammation, and optimal outcomes generally require a combination of immunosuppression and arrhythmia-directed therapies [25]. Quinidine should be used for refractory VF storm. It deserves special consideration in patients with recurrent polymorphic VT or VF driven by Purkinje triggers or primary electrical disorders. Through inhibition of the transient outward potassium current (Ito), quinidine may suppress VF in patients with Brugada syndrome, idiopathic VF, short-coupled VF, and selected Purkinje-mediated VF storms. Although limited by availability and adverse effects, quinidine remains an important therapeutic option when conventional therapies fail, or catheter ablation is not immediately feasible [2,26]. Isoproterenol is used in Brugada syndrome and idiopathic VF. While sympathetic blockade is generally preferred in ES, important exceptions exist. In patients with Brugada syndrome associated VF storm or selected forms of idiopathic VF, intravenous isoproterenol may suppress recurrent ventricular arrhythmias by increasing inward calcium current and reducing transmural repolarization heterogeneity. Therefore, identification of the underlying arrhythmia mechanism remains critical when selecting autonomic therapies [2]. Device programming ICD programming after VT ablation aims to minimize inappropriate shocks, maximize ATP efficacy, and allow prolonged detection times to avoid unnecessary shock for self-terminating arrhythmias. The 2019 HRS/EHRA/APHRS/LAHRS Expert Consensus Statement acknowledges that data on optimal ICD programming post-VT ablation are limited, as most programming studies were conducted in patients without prior VT. For VT detection at 10-20 bpm margin below the slowest documented VT rate if the patient has slower VT. For patients with faster VT, higher detection rate (>200 bpm) may be appropriate [22]. Noninvasive programmed stimulation (NIPS) performed post-ablation can guide individualized ICD programming based on inducibility results [27]. Early rehabilitation Survivors of ES often experience profound physical deconditioning because of prolonged immobilization, deep sedation, repeated defibrillation, and critical illness. In parallel, psychological sequelae are common, including anxiety, hypervigilance to cardiac symptoms, and fear of recurrent shocks, which may lead to maladaptive avoidance of physical activity. Accordingly, early multidisciplinary rehabilitation is essential. Early bedside mobilization, initiated once hemodynamic stability is achieved, plays a pivotal role in preventing further functional decline. However, in patients with ongoing ventricular arrhythmia risk, rehabilitation must be carefully balanced against the potential for arrhythmia exacerbation. Although activity was necessarily limited during the acute phase of ES, low-intensity rehabilitation was initiated in bed, and with progressive stabilization, the patient was ultimately able to ambulate independently. Equally important is the management of psychological complications. Frequent ICD shocks and critical illness may precipitate acute stress reactions, delirium, or features consistent with post-traumatic stress disorder [28]. Close collaboration with psychiatry is therefore crucial. In our case, the patient developed transient delirium following extubation, prompting early psychiatric consultation and co-management. Pharmacologic therapy was carefully selected to minimize the risk of QT prolongation, and this approach contributed to subsequent stabilization of mental status. Integration into a structured cardiac rehabilitation program combined with psychological support facilitates safe reintegration into daily activities, restoration of functional capacity, and mitigation of fear-driven inactivity. This holistic approach underscores the importance of addressing both the physical and psychological consequences of ES as part of comprehensive long-term care. Connecting with the patient Continuity of care is a cornerstone of long-term management following an episode of ES. Prior to discharge, patients should receive comprehensive and comprehensible instructions regarding medication adherence, activity recommendations, and warning signs that warrant medical attention. Explicit guidance on how to respond to ICD therapies, including when and how to report shocks, is essential to encourage appropriate help-seeking behavior while minimizing unnecessary panic-driven emergency visits. Establishing dedicated hospital contact pathways, such as direct electrophysiology clinic lines or remote monitoring alerts, enhances accessibility and reinforces patient confidence in ongoing support. In selected high-risk individuals, particularly those with recent recurrent arrhythmia, advanced cardiomyopathy, or significant anxiety, provision of direct clinician contact pathways may further reduce psychological distress and prevent avoidable emergency department utilization. Ultimately, long-term recovery extends beyond arrhythmia suppression alone. It depends on sustained therapeutic alliance, trust in the healthcare team, and reliable access to care, all of which foster adherence, psychological reassurance, and stable reintegration into daily life. Home monitoring and long-term surveillance Remote ICD monitoring enables early detection of arrhythmia recurrence and device-related issues, allowing timely clinical intervention before clinical deterioration occurs. Continuous remote surveillance not only identifies recurrent ventricular arrhythmias and inappropriate therapies but also facilitates prompt recognition of lead malfunction, battery concerns, or changes in patient status [29,30]. Comprehensive long-term care extends beyond device surveillance alone. It should incorporate structured electrophysiology follow-up to reassess arrhythmic substrate and device programming, ongoing optimization of guideline-directed heart failure therapy to reduce recurrent arrhythmic risk, and systematic psychological screening to address anxiety, depression, or post-shock distress. Such an integrated, multidisciplinary approach ensures sustained arrhythmia control, enhances patient confidence, and supports functional and emotional recovery over time. Conclusion Management of VT/VF storm requires a structured, stepwise escalation strategy: from sedation and beta-blockade to intravenous antiarrhythmic therapy, neuromodulation, and catheter ablation, followed by advanced ablation approaches when needed. Beyond acute stabilization, comprehensive care should extend to rehabilitation, medication optimization, patient engagement, and home monitoring to ensure sustained long-term outcomes. The presented cases illustrate distinct mechanisms, scar-mediated reentry in NICM and Purkinje-triggered VF after MI, yet both required adherence to the same systematic flow. Successful management extends beyond arrhythmia termination to include functional recovery, psychological support, and sustained patient engagement. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.